Please login to the form below

Not currently logged in
Email:
Password:

Invokana

This page shows the latest Invokana news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana gets lifeline with new kidney disease approval

J&J’s Invokana gets lifeline with new kidney disease approval

Sales of Johnson &Johnson’s type 2 diabetes therapy Invokana have been heading downwards since being linked to lower limb amputation risks, but the company hopes a new FDA approval could ... Since Invokana’s troubles, sales of  Farxiga and Jardiance

Latest news

More from news
Approximately 21 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken Invokana (the 2nd entrant).

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and

  • Pharma deals during April 2013 Pharma deals during April 2013

    Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor—Invokana (canagliflozin). In this deal, Merck gets to extend the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...

Infographics